ABSTRACT
The comparative efficacy of roxatidine and ranitidine in the treatment of patients with acute duodenal ulcer was assessed at 4 and 6 weeks in this multicenter study. Ninety-four of 192 patients were given roxatidine in a single nightly dose of 150 mg, and 98 patients were given ranitidine in a single nightly dose of 300 mg. All the patients had endoscopically proven duodenal ulcer. Of the 171 assessable patients, ulcers were healed in 88% of the roxatidine group (73 of 83) and in 84% of the ranitidine group (74 of 88). No serious adverse events were reported in either group. We conclude that roxatidine 150 mg once daily is as effective and safe for the treatment of acute duodenal ulcer as ranitidine 300 mg once daily.
Subject(s)
Duodenal Ulcer/drug therapy , Histamine H2 Antagonists/therapeutic use , Piperidines/therapeutic use , Ranitidine/therapeutic use , Administration, Oral , Adult , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Duodenal Ulcer/pathology , Endoscopy, Digestive System , Female , Follow-Up Studies , Histamine H2 Antagonists/administration & dosage , Histamine H2 Antagonists/adverse effects , Humans , Male , Piperidines/administration & dosage , Piperidines/adverse effects , Ranitidine/administration & dosage , Ranitidine/adverse effects , Retrospective Studies , Safety , Treatment OutcomeABSTRACT
Ramipril, a once-a-day angiotensin-converting enzyme inhibitor, was studied in the treatment of mild-to-moderate hypertension in 240 patients. A total of 194 patients (111 women and 83 men; mean +/- SD age, 46.0 +/- 11.5 years) were considered assessable for study. After a 2-week placebo washout phase, all patients received ramipril 2.5 mg once daily for 4 weeks. At 4 weeks, blood pressure was evaluated for response to therapy. Responders to 2.5 mg were continued on the same dose; nonresponders received 5 mg once daily for another 4 weeks. Results showed that 91% of patients responded after 8 weeks of therapy, 60% to 2.5 mg and 31% to 5 mg. Ramipril was well tolerated and, because of its long half-life, can be considered a true once-a-day angiotensin-converting enzyme inhibitor for the treatment of patients with mild-to-moderate hypertension.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Hypertension/drug therapy , Ramipril/therapeutic use , Administration, Oral , Adult , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Blood Pressure/drug effects , Body Weight , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Male , Middle Aged , Pakistan , Ramipril/administration & dosage , Safety , Treatment OutcomeABSTRACT
Twenty-five patients with typhoid fever, who were resistant to amoxicillin and chloramphenicol, were successfully treated with ofloxacin. Ofloxacin was administered at a dosage of 200 mg three times daily for 7 to 10 days. In a few seriously ill patients, a dosage of 400 mg three times daily for 3 days, followed by 200 mg three times daily for 4 to 7 days, was administered. This study confirmed the presence of resistant strains of Salmonella typhi. These strains were resistant to the commonly used drugs, chloramphenicol and amoxicillin. Ofloxacin was found to be well tolerated and effective in treating typhoid fever.
Subject(s)
Chloramphenicol Resistance , Ofloxacin/therapeutic use , Penicillin Resistance , Typhoid Fever/drug therapy , Adolescent , Adult , Female , Fever/drug therapy , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Ofloxacin/adverse effects , Salmonella typhi/drug effects , Typhoid Fever/microbiologyABSTRACT
Chloramphenicol was used to treat confirmed typhoid fever in 50 patients, but 14 patients did not respond to treatment. When their treatment was changed to ofloxacin (400 mg twice daily for six days, followed by 200 mg for eight days, administered orally), all responded. Ofloxacin was well tolerated and appears to be an effective agent in the treatment of typhoid fever.
Subject(s)
Chloramphenicol/therapeutic use , Ofloxacin/therapeutic use , Typhoid Fever/drug therapy , Adolescent , Adult , Aged , Chloramphenicol Resistance , Female , Humans , Male , Middle Aged , Pakistan , Salmonella typhiABSTRACT
Poly Vinly Chloride (PVC) is a very durable, practical and economical plastic, which is so wide spread in its use that it may become difficult to replace it. The annual amount of world production has been constantly increasing and has reached the figure of 8.5m tons. While PVC is so useful, the health hazards which accompany this plastic are causing alarm in the industrially developed countries. The hazards are severe and include defects such as Haemangioendothelial sarcoma (Angiosarcoma) of the liver, Acro-Osteolysis of the fingers and Sclerodermic type skin lesions. This paper illustrates the recent developments, the clinical findings and the measures necessary to control the disease. Moreover, this paper should help alerting the health authorities in the developing countries about the health hazards involved in the manufacture and utilization of PVC. Due to the restrictions imposed on PVC producing plants, there is a real eventuality that these plants may be transferred to the developing countries, where this disease is still unknown.
